InSilico Medicine (HKG:3696) booked $352.3 million in attributable loss for 2025, widening from a loss of $17.1 million in 2024, according to a Hong Kong bourse filing Sunday.

Shares of the AI-driven drug discovery and development company gained over 7% in morning trade Monday.

Loss per share was $4.48, compared with $0.24 in the prior year.

Revenue fell 35% year on year to $56.2 million, figures showed.

Meanwhile, in a separate announcement, the firm said it entered into a licensing and drug discovery collaboration with Eli Lilly.

Under the agreement, InSilico Medicine granted Eli Lilly an exclusive worldwide license to develop medicines using its technology.

InSilico Medicine said it is eligible to receive $115 million in upfront payment plus up to $2.75 billion in milestone-related payments. The company will also receive royalties on sales of drugs commercialized under the deal.